S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials

Abstract Representing the common endpoint of various cardiovascular disorders, heart failure (HF) shows a dramatically growing prevalence. As currently available therapeutic strategies are not capable of terminating the progress of the disease, HF is still associated with a poor clinical prognosis....

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular and cellular cardiology 2011-05, Vol.50 (5), p.777-784
Main Authors: Rohde, David, Brinks, Henriette, Ritterhoff, Julia, Qui, Gang, Ren, Shumei, Most, Patrick
Format: Article
Language:English
Subjects:
Animals
Calcium
Cardiovascular
Energy Metabolism
Gene therapy
Genetic Therapy - methods
Heart failure
Heart Failure - genetics
Heart Failure - therapy
Humans
Mitochondria
Myofilaments
Reticulum
S100 Proteins - genetics
S100A1
Sarcoplasmic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Representing the common endpoint of various cardiovascular disorders, heart failure (HF) shows a dramatically growing prevalence. As currently available therapeutic strategies are not capable of terminating the progress of the disease, HF is still associated with a poor clinical prognosis. Among the underlying molecular mechanisms, the loss of cardiomyocyte Ca2+ cycling integrity plays a key role in the pathophysiological development and progression of the disease. The cardiomyocyte EF-hand Ca2+ sensor protein S100A1 emerged as a regulator both of sarcoplasmic reticulum (SR), sarcomere and mitochondrial function implicating a significant role in cardiac physiology and dysfunction. In this review, we aim to recapitulate the translation of S100A1-based investigation from first clinical observations over basic research experiments back to a near-clinical setting on the verge of clinical trials today. We also address needs for further developments towards “second-generation” gene therapy and discuss the therapeutic potential of S100A1 gene therapy for HF as a promising novel strategy for future cardiologists. This article is part of a Special Section entitled “Special Section: Cardiovascular Gene Therapy”.
ISSN:0022-2828
1095-8584
DOI:10.1016/j.yjmcc.2010.08.012